Figure 3.

Effects of GSK‐induced TRPV4 activation on GP bladder functional outputs. A(i), Median force of mucosal and full‐thickness contractions generated by various GSK concentrations. Significantly stronger contractions evoked by 1 μM. A(ii), Corresponding median ATP release from same bladder strips. All concentrations significantly increased—ATP release (0.3 μM n = 10; 0.5 μM n = 8; 1 μM n = 18); control: 107 ± 39 pmoles/g tissue/min. B, Relationship between GSK1016790A‐induced contractions and ATP release. No correlation observed between the contraction and level of ATP release in GP FT strips. Spearman correlation coefficient r_s of 0.02374, n = 18. C, Median values of GSK‐induced contractions (n = 8), with record of single 50 μM carbachol (CCh) contraction for reference (n = 1) (note Log2 y axis). D, Record of sustained contraction induced by 1 μM GSK in FT strip (i) (and mucosal strip) and transient CCh‐induced contraction in FT strip. Median values [25%, 75%]. A(ii), drug intervention vs. control (basal levels [BL]) compared using Wilcoxon's, *P < .05; All graphs: data sets compared using Mann‐Whitney